Entering the Final Months – Successful OSTEOproSPINE Consortium Meeting in Dubrovnik
On 12 and 13 October 2022, the OSTEOproSPINE consortium came to Dubrovnik for their 5th Progress Meeting. After two years of virtual meetings, the partners were really happy to meet in person for the set-up of the final months of the project. The meeting was linked to the 13th BMP Conference hosted by the OSTEOproSPINE Coordinator University of Zagreb School of Medicine from 8 October to 12 October 2022.
In the beautiful setting of the Dubrovnik autumn season, the OSTEOproSPINE meeting started off with a short recapitulation of the BMP conference presented by Professor Vukicevic. After that, it was time to discuss management issues and tasks, led by UZSM. The Eurice Team gladly took the opportunity to discuss the review meeting that had just taken place two weeks earlier, as well as the next steps in the communication, dissemination and exploitation of OSTEOproSPINE. Following a more general discussion, it was time for the consortium to explore the Old Town of Dubrovnik in a guided tour and have dinner right in the city.
The second meeting day focused on clinical as well as research activities and sustainability planning. All scientific work packages were presented by the WP leaders and the partners discussed open questions regarding the clinical trial and data management. Professor Windhager (MUW) presented the latest developments in the clinical trial and Ana Ivanovska (CF) reported trial management activities. Mihaela Peric (UZSM) and Bernhard Liegl (QBEX) gave an overview of the regulatory affairs and Przemyslaw Mistur (2KMM) reported the status of the data management activities and challenges. Prof. Vukicevic (UZSM) and Prof. Pećin (UZFVM) presented results from the testing of new formulations while Hermann Oppermann (GEN) gave a status update on the medicinal product supply. The consortium discussed the sustainability of the project in the plenary, exploring opportunities to carry on the work even after the end of OSTEOproSPINE.
In the afternoon, the partners formed different working groups for in-depth discussions on the clinical trial, regulatory as well as data management questions. The meeting ended with a joint dinner in the evening.
Find out more about OSTEOproSPINE by following the link: https://osteoprospine.eu
